USC.edu
Are You a Patient?

Jonathan S. Lopresti, MD

Associate Professor of Clinical Medicine

Image of Jonathan S. Lopresti, MD
Is this your profile? Click to edit
Phone +1 323 226 4632
Email [email protected]
CTSI Profile

Overview

A native of Los Angeles, Dr. LoPresti received both his medical degree and his Ph.D. in physiology from the University of Southern California. He first joined the Trojan family in 1974 as a biology undergraduate and finished his residency at the LAC+USC Medical Center ten years later. Dr. LoPresti has contributed to over fifty presentations, recently lecturing on a case of an aggressive Papillary Thyroid Cancer arising in the third trimester of pregnancy. In addition, he has had leadership roles in the American Thyroid Association and has been published in numerous journals, abstracts and book chapters.

Awards

  • Department of Medicine, USC: Attending of the Year for Internal Medicine, 1997
  • Keck School of Medicine of USC: Professor of the Year for Fourth Year Students, 1998
  • Keck School of Medicine of USC: Faculty Teaching Award, Year II, 2015
  • Keck School of Medicine of USC: Faculty Teaching Award, Year IV, 2015

Publications

  • Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by Different Methodologies: IMA, LC-MS/MS, and RIA. J Clin Endocrinol Metab. 2024 11 18; 109(12):3254-3263.. View in PubMed
  • Does Reverse Triiodothyronine Testing Have Clinical Utility? An Analysis of Practice Variation Based on Order Data from a National Reference Laboratory. Thyroid. 2018 07; 28(7):842-848.. View in PubMed
  • Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab. 2014 Dec; 99(12):4589-99.. View in PubMed
  • Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9.. View in PubMed
  • MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 01; 20(23):6034-44.. View in PubMed
  • How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes. 2014 Oct; 21(5):394-404.. View in PubMed
  • Is an isolated TSH elevation in chronic nonthyroidal illness “subclinical hypothyroidism”? J Clin Endocrinol Metab. 2014 Nov; 99(11):4015-26. Kaptein EM, LoPresti JS , Kaptein MJ . View in PubMed
  • BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep; 24(9):1385-93.. View in PubMed
  • In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid. 2014 Jul; 24(7):1127-33.. View in PubMed
  • Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid. 2010 Jun; 20(6):587-95.. View in PubMed

Similar People